Motzer RJ, et al. N Engl J Med 2013;369(8):722.
COMPARZ. Fase III
SEGURIDAD.
PAZOPANIB: ENSAYOS CLÍNICOS.
Adverse Event
1
Pazopanib
(n = 554) %
Sunitinib
(n = 548) %
All Grades
All Grades
Any event
2
>99
>99
Diarrhea
63
57
Fatigue
55
63
Hypertension
46
41
Nausea
45
46
Decreased appetite
37
37
ALT increased
31
18
Hair color changes
30
10
Hand-foot syndrome
29
50
Taste alteration
26
36
Thrombocytopenia
10
34
